Recent events
Recent events tied to this brand in public sources.
Back to profile33 entries · Page 2 of 2
2021
Moderna announces vaccine production expansion and 2022 target
Moderna announced that it was expanding its in-house and partner COVID-19 vaccine production capabilities, with a 2022 production target of 1.4 billion doses.
2021
SiO2 Materials Science increases vaccine-vial production
SiO2 Materials Science increased production from about 10 million vials per year to 10 million per month and reported operating four manufacturing sites instead of one. It said it had shipped vials to Moderna and other companies developing COVID-19 vaccines.
2021
Uber and Moderna announce a COVID-19 vaccine collaboration
Uber and Moderna announced a collaboration around COVID-19 vaccination. The confirmed initiative is to provide reliable information about vaccine safety through Uber’s consumer app; the companies also discussed other possible options.
2020
FDA authorized emergency use of Moderna's COVID-19 vaccine
The U.S. Food and Drug Administration authorized emergency use of Moderna's COVID-19 vaccine on Friday, December 18, 2020.
2020
Moderna reports vaccine documents accessed in cyberattack
Moderna said the European Medicines Agency informed it that certain documents related to pre-submission discussions about its COVID-19 vaccine candidate had been unlawfully accessed in a cyberattack on the regulator. Moderna said its submission did not include information identifying individual study participants.
2020
Singapore signs advance-purchase agreements with three vaccine makers
Singapore signed advance-purchase agreements with Moderna, Pfizer-BioNTech and Sinovac for COVID-19 vaccines. The report said the first Pfizer vaccine batch was due to arrive by the end of December, with the other companies' vaccines expected to arrive the following year.
2020
Roche partners with Moderna on vaccine trials
Roche announced a partnership with Moderna to use Roche’s Elecsys Anti-SARS-CoV-2 S antibody test in Moderna’s mRNA-1273 vaccine research trials.
2020
Moderna reports second-quarter 2020 results
Moderna reported second-quarter revenue of $66.4 million and a loss of $116.7 million.
2020
Moderna enters Canadian vaccine supply agreement
The article reports that Canada signed an agreement with Moderna for the supply of its potential COVID-19 vaccine candidate, mRNA-1273.
2020
Moderna announces vaccine manufacturing collaboration with Catalent
Moderna announced a collaboration with Catalent for large-scale manufacturing of its potential COVID-19 vaccine. Catalent was to handle vial filling and packaging and provide staffing to support production of an initial 100 million doses.
2020
Moderna announces a CFO change
Moderna announced a C-suite change on Thursday. The supplied article does not identify the appointee.
2020
FDA approves Moderna vaccine candidate for Phase II trial
Moderna announced that its coronavirus vaccine candidate received emergency Phase II approval from the FDA. Moderna said it would begin the next round of trials with 600 participants shortly.
2020
Moderna and Lonza announce vaccine manufacturing collaboration
Moderna and Lonza announced a 10-year collaboration under which Lonza will establish manufacturing sites in the United States and Switzerland for Moderna’s experimental coronavirus vaccine, subject to regulatory approval.